DURECT

DURECT harnesses epigenetic modulation to potentially treat serious and life-threatening conditions, including acute organ injury and cancer. Our unique approach targeting dysregulated DNA methylation has the potential to change the course of disease and improve patients' lives... Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies.

Also known as: Durect Corporation

Primary location: Cupertino United States